Sudeep Pharma Ltd (SUDEEPPHRM) Q1 FY27 Earnings Call: Bisglycinate Sales Surpass Full-Year FY26 Total, Battery Customer Funnel Expands to Eight

Sudeep Pharma Ltd held its Q1 FY27 earnings call on August 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue up 27% YoY; margins resilient despite LPG disruption

• Revenue of Rs.158.3 crore in Q1 FY 2026-2027, up 27% YoY from Rs.124.9 crore in Q1 FY 2025-2026, driven by broad-based growth across pharma, food & nutrition, and specialty ingredients.
• EBITDA of Rs.54.9 crore in Q1 FY 2026-2027, up 25% YoY; EBITDA margin held at 34.7% despite severe LPG supply crisis that pushed April utilization to ~33% of normal.
• PAT of Rs.40.6 crore in Q1 FY 2026-2027, from Rs.31.3 crore in Q1 FY 2025-2026; PAT margin improved to 25.6% from 25.0%.
• Pharma, Food & Nutrition segment contributed 69% of Q1 FY 2026-2027 revenue; Specialty Ingredients contributed 31%. Exports remained the dominant revenue driver.
• Management expects strong momentum to continue into Q2 FY 2026-2027, with a historically stronger second half supporting "a year of strong growth for FY 2026-2027".

Bisglycinate surges; battery funnel expands to 8 customers

• Bisglycinate sales in Q1 FY 2026-2027 surpassed the entire FY 2025-2026 total; management expects it to become a top-two or top-three product though material contribution is not expected in FY 2026-2027.
• Pharma, Food & Nutrition segment grew 30% YoY in Q1 FY 2026-2027, predominantly volume-driven (~3% from currency). Management views this growth rate as sustainable at scale in FY 2027-2028 once new greenfield capacity is fully utilized.
• Specialty Ingredients grew 19% YoY in Q1 FY 2026-2027, below trend due to LPG shortage; normalized operations resumed in Q2 FY 2026-2027, and historical growth trajectory is expected to resume.
• Battery materials customer funnel expanded from six to eight customers for iron phosphate (LFP chemistry) as of Q1 FY 2026-2027; management emphasized the need to convert approvals into binding orders.
• Two additional strategic MOUs signed in Q1 FY 2026-2027 with leading South Korean cathode active material manufacturers and their cell manufacturing partners.
• China's Decree 837 cited by management as reinforcing "the strategic importance of non-China suppliers for the battery supply chain".

EBITDA target of 37-38%; specialty margins compressed by NSS headwind

• EBITDA margin target of 37-38% — management aims to sustain this range, supported by international markets with stronger margin profiles; historically achieved before sales team investments.
• Specialty segment margins fell to 26% in Q1 FY 2026-2027 due to sub-50% utilization for half the quarter and a challenging quarter for the NSS (European subsidiary) business. Core specialty business (ex-NSS) maintained margins in the mid-30s.
• NSS customer issue — a major infant formula client in Ireland scaled down operations due to the energy crisis, delaying purchase orders. Management expects "flattish to single-digit growth for NSS in FY 2026-2027".
• NSS margins expected to track Indian specialty levels by FY 2027-2028 as new projects materialize and revenue grows; a new sales head has been hired to expand beyond Ireland.
• Cost pass-through for phosphates had marginal benefit in Q1 FY 2026-2027; the majority of sales with pass-through are expected in Q2 FY 2026-2027. Phosphoric acid prices rose ~50% during the quarter.
• Working capital target of 160-170 days steady-state (excluding battery inventory); long-term sustainable target of 150 days. Near-term inventory days elevated due to geopolitical logistics delays and battery material inventory build.

Battery scale-up; greenfield facility and LFP capacity roadmap

• Sudeep Advanced Materials (SAM) Phase 1 commissioning targeted by April 2027; major long-lead equipment deliveries expected by October 2026. Customer qualification funnel: 21 at lab validation, 16 at pilot scale, 7 completed commercial validation with active off-take discussions.
• Management optimistic about concluding two significant binding off-take agreements later in FY 2026-2027; early evaluation of expansion from 100 KTPA to 200 KTPA underway.
• For the new 21,000 ton greenfield facility, management guided for approximately one-third utilization in FY 2028-2029, with a "hockey stick" in utilization expected by FY 2029-2030.
• Management believes LFP will be the dominant battery chemistry for the next 5-7 years (FY 2026-2033), but noted that even if sodium-ion scales, it will require iron phosphate as a precursor, providing dual application for their product.
• At scale, steady-state asset turns for greenfield and battery facilities are expected to settle between 2.7x and 3.0x (period unspecified).
• New capacity will allocate ~50% to expand existing phosphate products and introduce new products (big glycinate, gluconate, citrate). Management expects to return to 37-38% EBITDA margins with ramp-up of new greenfield capacity.

Capacity inflection in H2 FY27; NSS drag near-term

• PFN capacity is nearly fully utilized — current capacity can be sweated for only a "couple of percent" additional growth; the next growth inflection depends on the greenfield facility being commissioned in Q3 FY 2026-2027.
• Greenfield facility at Navsari is undergoing regulatory approvals; FDA approval expected in Q2 FY 2026-2027, with commercial supplies starting in Q3 FY 2026-2027.
• NSS is expected to contribute flattish to single-digit growth in FY 2026-2027; management indicated that "historical growth momentum in specialty ingredients is sustainable for FY 2026-2027 and FY 2027-2028".
• Management evaluating scale-up from 100,000 to 200,000 KTPA capacity, contingent on binding offtake agreements with two large customers. Current target to reach 200 KTPA between calendar years 2030 and 2031.
• Optimum steady-state capacity utilization is 70-75%, depending on product mix (period unspecified).
• Logistics disruptions, elevated freight costs, and 50% increase in phosphoric acid prices were key headwinds in Q1 FY 2026-2027; price increases expected to largely offset input cost impact in Q2 FY 2026-2027.